和黃醫藥啟動歐美兩項治療晚期實體瘤或惡性血液腫瘤國際I期臨床試驗
和黃醫藥(HCM.US)公布,已啟動兩項「HMPL-306」的國際I期研究。「HMPL-306」是一種新型雙重靶向異檸檬酸脫氫(酉每)(IDH)1和2突變的選擇性小分子抑制劑。兩項研究分別用於治療晚期實體瘤患者及惡性血液腫瘤患者,均於美國和歐洲設立臨床試驗中心。
集團指,繼去年下半年中國I期研究啟動後,國際研究的首名患者已於今年3月25日接受給藥治療。新的研究標誌集團正進一步加速和擴展全球臨床研發業務。兩項多中心臨床試驗旨在評估「HMPL-306」的安全性、耐受性、藥代動力學、藥效學和初步療效。首項臨床試驗針對實體瘤(包括但不限於膠質瘤、軟骨肉瘤或膽管癌),而第二項臨床試驗針對伴有IDH1和/或IDH2突變的晚期復發性或難治性惡性血液腫瘤。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.